441 related articles for article (PubMed ID: 34945003)
21. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
22. Recent advancements in PARP inhibitors-based targeted cancer therapy.
Zhou P; Wang J; Mishail D; Wang CY
Precis Clin Med; 2020 Sep; 3(3):187-201. PubMed ID: 32983586
[TBL] [Abstract][Full Text] [Related]
23. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
24. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
25. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
26. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
[TBL] [Abstract][Full Text] [Related]
27. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
Yakovlev VA; Sullivan SA; Fields EC; Temkin SM
Front Oncol; 2023; 13():1124147. PubMed ID: 36910637
[TBL] [Abstract][Full Text] [Related]
29. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.
Langelier MF; Lin X; Zha S; Pascal JM
Sci Adv; 2023 Mar; 9(12):eadf7175. PubMed ID: 36961901
[TBL] [Abstract][Full Text] [Related]
30. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
31. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
32. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
33. Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
Junior HLR; de Oliveira RTG; de Paula Borges D; Costa MB; Farias IR; Dos Santos AWA; Magalhães SMM; Pinheiro RF
Med Oncol; 2019 Oct; 36(12):99. PubMed ID: 31667665
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E; Antonarakis ES
Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
[TBL] [Abstract][Full Text] [Related]
35. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
[TBL] [Abstract][Full Text] [Related]
36. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Rose M; Burgess JT; O'Byrne K; Richard DJ; Bolderson E
Front Cell Dev Biol; 2020; 8():564601. PubMed ID: 33015058
[TBL] [Abstract][Full Text] [Related]
37. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.
Kohl V; Flach J; Naumann N; Brendel S; Kleiner H; Weiss C; Seifarth W; Nowak D; Hofmann WK; Fabarius A; Popp HD
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623402
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.
Zhao Q; Ma P; Fu P; Wang J; Wang K; Chen L; Yang Y
Front Pharmacol; 2022; 13():912256. PubMed ID: 35784751
[No Abstract] [Full Text] [Related]
39. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
40. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
Gupta SK; Smith EJ; Mladek AC; Tian S; Decker PA; Kizilbash SH; Kitange GJ; Sarkaria JN
Front Oncol; 2018; 8():670. PubMed ID: 30723695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
